Floatz logo

hsp990

Amyotrophic Lateral Sclerosis (ALS)

Universitaire Ziekenhuizen KU LeuvenN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the Amyotrophic Lateral Sclerosis (ALS) cohort.

Asset / SponsorPhaseRating
Mci-186
Tanabe Pharma Corporation
Phase 3BB
L-Carnitine
ChaodongWang
Phase 4BB
Tvp-1012
Richard Barohn, MD
Phase 2B
Mecobalamin
Eisai Co., Ltd.
Phase 2/3B
Masitinib
AB Science
Phase 3B

View all 36 →

Same molecule, other indications

hsp990 is also rated in:

Advanced Solid MalignanciesDormant
CC
Indicative ·
44 / 100
View asset →
cancerDormant
C
Indicative ·
36 / 100
View asset →
Parkinson's Disease (PD)Dormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →